Data has always been at the heart of the research-based biopharmaceutical industry. Until recently, clinical trial data was the key determinant of a drug’s success or failure. Now, as the healthcare system shifts towards value-focused outcomes, that success depends on a far wider expanse of data, including outcomes and cost data, adherence rates and, increasingly, patient-reported data, behavioral and social media data.

Achieving more cost-effective, better quality care demands more tailored, cost-effective treatments, more integrated care, better disease management, and more effective prevention. That requires stakeholders to access, assimilate, and interpret multiple data sources – be it to figure out how to recruit and run the optimal clinical trial, to properly understand care gaps and patient need, to track patients’ moves through the health system, or to predict who is at-risk for an adverse event.

Those data sources are increasingly accessible, and so are the tools to analyze and interpret them. The thriving data market has attracted new players and presents huge opportunities. The challenges lie in how to most effectively integrate and use the data, and in adapting mindsets, resources, and organizational structures to take full advantage of it.

Key Questions Answered in the Report:

• What types of data are being generated and utilized by different healthcare stakeholders?
• How does the data need and utilization differ between different healthcare stakeholders?
• What is the role of the data analytics providers in the current data landscape?
• What challenges are facing the data market and how will they be overcome?
• How is data enabling population health management?
• How are pharma companies using big data in healthcare?